Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
4DMedical Ltd ( (AU:4DX) ) has shared an announcement.
4DMedical has disclosed changes in the equity interests of three directors following a recent capital placement, detailing option exercises and share movements that modestly increase insider ownership. Chief executive Andreas Fouras and director Julian Sutton both exercised substantial tranches of options, partially funded by selling existing shares, resulting in net increases of 1,587,757 and 2,000,000 shares respectively, while director John Livingston saw a reduction in his potential stake through the lapse of 636,576 options without selling any shares, signalling continued alignment of key management with shareholders as the company advances its respiratory imaging technology platform.
The most recent analyst rating on (AU:4DX) stock is a Hold with a A$4.50 price target. To see the full list of analyst forecasts on 4DMedical Ltd stock, see the AU:4DX Stock Forecast page.
More about 4DMedical Ltd
4DMedical Limited is a global medical technology company focused on revolutionising respiratory care through advanced imaging and artificial intelligence. Its patented XV Technology transforms standard lung scans into detailed functional insights, enabling earlier and more precise detection, diagnosis and monitoring of lung disease. The company offers a growing portfolio of software products, including FDA-cleared XV Lung Ventilation Analysis Software (XV LVAS), CT LVAS and its CT:VQ solution, all delivered via a SaaS model that integrates into existing hospital infrastructure and has been strengthened through the 2023 acquisition of AI imaging specialist Imbio.
Average Trading Volume: 5,078,969
Technical Sentiment Signal: Buy
Current Market Cap: A$2.61B
See more data about 4DX stock on TipRanks’ Stock Analysis page.